Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 13/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.39 |
| ▸ | ME2 | P23368 | 2/20 | 0.37 |
| ▸ | ME1 | P48163 | 2/20 | 0.37 |
| ▸ | ME3 | Q16798 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31435193 | 0.79 | HCAR2 (0.39) | EGLN1HCAR2ME2ME1ME3 | |
| SCHEMBL11899892 | 0.78 | EGLN1 (0.44) | EGLN1GAAALKBH2 | |
| SCHEMBL14822080 | 0.77 | EGLN1 (0.63) | EGLN1ALKBH2 | |
| SCHEMBL11900004 | 0.76 | EPHX2 (0.44) | EGLN1HCAR2 | |
| SCHEMBL23957800 | 0.76 | KCNJ1 (0.56) | EGLN1 | |
| SCHEMBL28429024 | 0.75 | EGLN1 (0.40) | EGLN1 | |
| SCHEMBL30401307 | 0.75 | EGLN1 (0.46) | EGLN1 | |
| SCHEMBL18789238 | 0.75 | KDM4E (0.49) | EGLN1 | |
| SCHEMBL29972961 | 0.75 | KCNJ1 (0.53) | EGLN1 | |
| SCHEMBL28938099 | 0.75 | EGLN1 (0.40) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| EP-2694472-A2 | SULFONAMIDE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
| WO-2012137982-A9 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-14 | — | — | WO | disclosed |
| WO-2012137982-A2 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | EGLN1 3774/4885HCAR2 172/4885ME2 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.